Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
GIMEMA ALL2820
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
- NCT04722848 ↗
- Active, not recruiting
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Deep
We haven't built an HCP commentary report on GIMEMA ALL2820 (ponatinib + blinatumomab in Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GIMEMA ALL2820 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 22 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment With Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); ALL, Adult; Philadelphia-Positive ALL
- Interventions
- Ponatinib + Blinatumomab; Chemotherapy + Imatinib
- Arms
- Ponatinib+Blinatumomab · Experimental
- Chemotherapy+Imatinib · Active comparator
- Enrollment
- 236
- Primary outcomes
- Number of patients who are event-free
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Start
- Sep 8, 2021
- Primary completion
- Sep 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04722848 · updated Jan 23, 2025
Publications
linked from the registry- Chiaretti S, Piciocchi A, Skert C, Leoncin M, Borlenghi E, Cattaneo C, Di Trani M, Elia L, Almici G, Cardinali D, Kaiser F, Lussana F, Fiumara PF, Maugeri C, Alati C, Martino M, Ansuinelli M, Lucco Navei G, Mattei D, Soddu S, Messina M, Marino MR, Mancini V, Chiusolo P, Scappini B, Martelli MP, Salutari P, Cerrano M, Serio B, Cucca A, Luppi M, Pochintesta L, Pasciolla C, Romani C, Mosna F, Bonifacio M, Tanasi I, Fracchiolla NS, Bocchia M, Imbergamo S, Califano C, Nunziata GR, Annunziata M, Mule A, Zappasodi P, Mastaglio S, Butera S, Della Porta MG, Porretto F, Lunghi M, De Bellis E, Todisco E, Basilico CM, Fazi P, Rambaldi A, Bassan R, Foa R; GIMEMA Investigators. Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. N Engl J Med. 2026 Oct 15;395(15):1483-1494. doi: 10.1056/NEJMoa2606208. PubMed 42874102